The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis

ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis

February 1, 2013 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON, D.C.—Will we witness dramatic breakthroughs in treating osteoarthritis (OA) in the coming decade? That’s the question three experts sought to address at a presentation titled, “Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?” at the 2012 ACR/ARHP Annual Meeting, held here November 9–14. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
Explore This Issue
February 2013
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA

Novel treatment strategies for OA aim to relieve symptoms like pain, to rebuild or replenish deteriorated cartilage and bone, or to replace the damaged joint altogether through surgery. Every treatment comes with potential adverse effects, and some lack measurable efficacy, the panelists noted. Most importantly, they stressed that rheumatologists use nonpharmacologic strategies first and that future strategies should slow disease progression through early detection and intervention efforts.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A number of currently available pharmacologic options enable rheumatologists to treat OA pain and other symptoms, said Marc Hochberg, MD, MPH, professor of medicine at the University of Maryland School of Medicine in Baltimore. He stressed to the audience that when treating their OA patients, rheumatologists should first offer guidance on nondrug approaches like exercise and weight reduction, then add layers of drugs as necessary. Treating OA pain effectively often helps patients achieve better physical function and, in turn, achieve better sleep and other positive outcomes, he said.

Acetaminophen is no longer strongly recommended as the first option to treat OA due to its minimal efficacy on pain and lack of efficacy on function and stiffness, Dr. Hochberg noted. Although it is safer for the upper gastrointestinal tract than traditional nonsteroidal antiinflammatory drugs (NSAIDs), there is evidence for liver-related side effects with its long-term use, he said. The U.S. Food and Drug Administration recommends no more than 3,000 milligrams of acetaminophen per day, and rheumatologists should warn OA patients about taking over-the-counter drugs for colds that contain acetaminophen in addition to their regular daily dose for pain, he added.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Effective treatments incurring minimal adverse effects are topical analgesics, including 1% diclofenac gel for pain and 1.5% diclofenac solution for the signs and symptoms of OA, said Dr. Hochberg. The main adverse effect is dry skin at the application site; this is seen less with the gel preparation. Among injectable treatments, intraarticular corticosteroids are efficacious at reducing pain, but viscosupplementation shows mild efficacy at best, he said.

Oral NSAIDS and Other Oral Drugs

Oral NSAIDs cause many adverse events that discourage their use for treating chronic OA pain, especially in patients 75 years and up, Dr. Hochberg said. When used in younger patients, the upper gastrointestinal adverse effects may be attenuated with misoprostol or proton pump inhibitors, Dr. Hochberg said. Although numerous NSAIDs are available, “there is no substantial evidence that one [nonselective] NSAID is more efficacious than another,” he said. He also stressed recent label changes on ibuprofen that state it can interfere with the antiplatelet effect of low-dose aspirin, reducing protection against heart attacks and strokes. “This is something our residents know nothing about,” Dr. Hochberg said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Osteoarthritis Tagged With: Osteoarthritis, Research, Stem Cells, TreatmentIssue: February 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
  • ACR/ARHP Annual Meeting 2012: New Treatments and Strategies Emerge for Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.